Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer
NCT03123263 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2019-09-09
Summary
This study retrospectively looks at changes in Echocardiographic parameters while using transtuzumab
Conditions
Sponsors & Collaborators
-
Texas Tech University Health Sciences Center, El Paso
lead OTHER
Principal Investigators
-
Sumit Gaur · TTUHSC El Paso
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-04-11
- Primary Completion
- 2019-02-26
- Completion
- 2019-02-26
Countries
- United States
Study Locations
More Related Trials
-
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients
NCT04293393 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Strain Imaging in Breast Cancer Patients Receiving Trastuzumab
NCT02080390 ·Status: COMPLETED
-
A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients
NCT03983382 ·Status: ACTIVE_NOT_RECRUITING
-
Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin
NCT02423356 ·Status: COMPLETED
-
A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
NCT01367028 ·Status: COMPLETED ·Phase: PHASE2
-
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
NCT05078190 ·Status: ACTIVE_NOT_RECRUITING
-
Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude
NCT05063643 ·Status: UNKNOWN
-
Characterization and Kinetic of Chemotherapy-induced Cardiovascular Toxicity in Breast Cancer
NCT05803889 ·Status: TERMINATED
-
Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer
NCT02102438 ·Status: WITHDRAWN ·Phase: NA
-
Bilingual Breast Cancer Educational Intervention for Hispanic Women With Stage I, Stage II, or Stage III Breast Cancer and Their Families or Caregivers
NCT01043003 ·Status: COMPLETED ·Phase: NA
-
An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)
NCT02658461 ·Status: COMPLETED
-
Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy
NCT04928261 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
NCT00436566 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
NCT06486883 ·Status: RECRUITING ·Phase: PHASE2
-
Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab
NCT06881940 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Cardiotoxicity of Adjuvant Trastuzumab
NCT00858039 ·Status: COMPLETED
-
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
NCT04962425 ·Status: UNKNOWN
-
Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer
NCT00533936 ·Status: UNKNOWN ·Phase: PHASE2
-
TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer
NCT04094896 ·Status: UNKNOWN ·Phase: PHASE2
-
Cardiac Toxicity in Medical Treatment of Breast Cancer
NCT02440620 ·Status: COMPLETED
-
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
NCT00944047 ·Status: COMPLETED ·Phase: PHASE2
-
Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
NCT00875238 ·Status: COMPLETED
-
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
NCT05708235 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index
NCT05728268 ·Status: RECRUITING ·Phase: PHASE2
-
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
NCT00464646 ·Status: COMPLETED ·Phase: PHASE2